Kiromic Biopharma Inc
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-s… Read more
Kiromic Biopharma Inc (KRBP) - Total Assets
Latest total assets as of December 2024: $8.54 Million USD
Based on the latest financial reports, Kiromic Biopharma Inc (KRBP) holds total assets worth $8.54 Million USD as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Kiromic Biopharma Inc - Total Assets Trend (2018–2024)
This chart illustrates how Kiromic Biopharma Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Kiromic Biopharma Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Kiromic Biopharma Inc's total assets of $8.54 Million consist of 38.6% current assets and 61.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Kiromic Biopharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kiromic Biopharma Inc's current assets represent 38.6% of total assets in 2024, a decrease from 64.0% in 2018.
- Cash Position: Cash and equivalents constituted 13.3% of total assets in 2024, down from 43.9% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Kiromic Biopharma Inc Competitors by Total Assets
Key competitors of Kiromic Biopharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Kiromic Biopharma Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Kiromic Biopharma Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Kiromic Biopharma Inc is currently not profitable relative to its asset base.
Kiromic Biopharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.16 | 0.22 | 3.67 |
| Quick Ratio | 0.16 | 0.22 | 3.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-17.60 Million | $ -15.95 Million | $ 2.37 Million |
Kiromic Biopharma Inc - Advanced Valuation Insights
This section examines the relationship between Kiromic Biopharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.55 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -29.8% |
| Total Assets | $8.54 Million |
| Market Capitalization | $47.64K USD |
Valuation Analysis
Below Book Valuation: The market values Kiromic Biopharma Inc's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Kiromic Biopharma Inc's assets decreased by 29.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Kiromic Biopharma Inc (2018–2024)
The table below shows the annual total assets of Kiromic Biopharma Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $8.54 Million | -29.78% |
| 2023-12-31 | $12.17 Million | +1.68% |
| 2022-12-31 | $11.97 Million | -61.06% |
| 2021-12-31 | $30.73 Million | +139.52% |
| 2020-12-31 | $12.83 Million | +383.65% |
| 2019-12-31 | $2.65 Million | +202.82% |
| 2018-12-31 | $876.00K | -- |